FLUO FluoGuide A/S
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The company was incorporated in 2018 and is based in Copenhagen, Denmark.…
Industry Peers
BiotechnologyKey Statistics
About FluoGuide (STO: FLUO)
›
FluoGuide (STO: FLUO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 29.50 SEK on 19 November 2026, down 30.9% over 52 weeks. Its 52-week range is 28.00 SEK to 47.80 SEK: the price is 38.3% below the high and 5.4% above the low.
Its market capitalisation is 482.30M SEK.
FluoGuide reports return on equity of -72.4% and revenue up 61.4% year over year.
It holds more cash than debt, a net cash position of 22.32M DKK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 54.51 SEK is 84.8% above the current price. The next earnings report is expected on 26 November 2026.